The Mouse Monoclonal anti-CD177 antibody has been validated for WB, FACS and IP. It is suitable to detect CD177 in samples from Human and Rhesus Monkey.
This antibody recognizes CD177 (Neutrophil Glycoprotein NB1). Antibodies against NB1 can be involved in neonatal alloimmune neutropenia (NAN). MEM-166 recognizes CD177 under Non-Reducing Conditions.
Flow cytometry (1/50 - 1/100): use 10 μL of the suggested working dilution to label 10^6 cells in 100 μL. Western blot: Non-reducing conditions. Immunoprecipitation. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Concentration
1.0 mg/mL
Buffer
PBS, 0.09 % Sodium Azide
Preservative
Sodium azide
Precaution of Use
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice
Avoid repeated freezing and thawing.
Storage
4 °C/-20 °C
Storage Comment
Store undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
Target
CD177
(CD177 Molecule (CD177))
Alternative Name
CD177
Background
CD177 (NP1), a glycosyl phosphatidylinositol (GPI) linked N glycosylated cell surface glycoprotein, was first described in a case of neonatal alloimmune neutropenia and analyses showed cell surface expression of a 60 kDa protein, 14 kDa greater than the predicted size, probably due to the presence of 3 potential N glycosylation sites. Immunohistochemistry demonstrated expression in bone marrow early erythroblasts, megakaryocytes, promyelocytes, and myelocytes. The neutrophil NB1 antigen (CD177) is expressed by 97 % of the caucasian population.Synonyms: HNA-2a, HNA2a, Human neutrophil alloantigen 2a, NB1, NB1 glycoprotein, PRV1, Polycythemia rubra vera protein 1